Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic Interactions Between HL237 and Tacrolimus in Healthy Male Subjects

NCT04633733 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.

NCT NCT04633733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04633733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic Interactions Between HL237 and Tacrolimus in Healthy Male Subjects
Lead sponsor
Hanlim Pharm. Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 22, 2020
Completion date
January 31, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy male volunteers